Defining the Basis of Fibromuscular Dysplasia (FMD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIcahn School of Medicine at Mount Sinai
About this trial
The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.
Eligibility criteria
Qualifiers
Patients of any age and freely willing to participate. For patients < 18 years of age consent will be via parents.
Fluency in either English or Spanish.
Signed, informed consent
For FMD, SCAD or CvAD subjects - a clinical diagnosis of FMD, SCAD or CvAD with fulfillment of standard diagnostic criteria.
Disqualifiers
Patients who have co-morbidities which reduces life expectancy to one year.
Patients with any solid organ or hematological transplantation, or those in whom transplantation is considered.
Active autoimmune disease.
Illicit drug use.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
600 Participants
are grouped into 4 trial groupsSponsors and collaborators
Source ClinicalTrials.gov